Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Evaluate the safety and tolerability of BPI-572270 in adult patients with specific RAS mutant advanced solid tumors.

Trial Details

NCT ID
NCT07435038
Phase
PHASE1 / PHASE2
Sponsor
Betta Pharmaceuticals Co., Ltd.
Status
RECRUITING
Cancer Type
Pancreatic Ductal Adenocarcinoma Pancreatic Cancer
Interventions
  • BPI-572270
Locations (sample)
  • Blacktown, New South Wales, Australia|-33.76667,150.91667
  • Randwick, New South Wales, Australia|-33.91439,151.24895
  • Sydney, New South Wales, Australia|-33.86785,151.20732
  • Bedford Park, South Australia, Australia|-35.02204,138.56815
  • Heidelberg, Victoria, Australia|-37.75,145.06667

Key Eligibility Criteria

  • Histologically confirmed advanced solid tumor with RAS mutations identified through deoxyribonucleic acid (DNA) sequencing.
  • Have received prior standard therapy appropriate for tumor type and stage.
  • Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Adequate organ function.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Ductal Adenocarcinoma Pancreatic Cancer Trials on Trialify →